We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with aut…
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$150M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$174M
▲ +25.9% YoY
Op. Margin
—
ROIC
-38.34%
▲ +1.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$110M
▲ +25.6% YoY
Op. Cash Flow (TTM)
-$109M
▲ +25.5% YoY
Net Debt
-$186M
Net Cash Position
Cash & Equiv.
$267M
Continue Research